Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms-Reference-Cited by-同舟云学术

Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms

Published:2021-07-22 Issue: Volume: Page:1-16
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Dahiya Mandeep¹,Dureja Harish¹

Affiliation:

1. Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2021.1955202

Reference120 articles.

1. The evolving epidemiology of hepatocellular carcinoma: a global perspective

2. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, drugs approved for liver cancer. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/liver. Accessed on 14 Aug, 2020.

3. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study

4. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib

5. Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluationin vitroandin vivo

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells;Annals of Hepatology;2024-11

2. Aurantio‑obtusin regulates lipogenesis and ferroptosis of liver cancer cells through inhibiting SCD1 and sensitizing RSL3;International Journal of Oncology;2024-08-13

3. WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation;Current Cancer Drug Targets;2024-06-10

4. CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics;Current Medicinal Chemistry;2024-01-12

5. Chitosan based sorafenib tosylate loaded magnetic nanoparticles: Formulation and in-vitro characterization;International Journal of Biological Macromolecules;2023-07